Hero image

Oncology

We’re working to invent a world where cancer isn’t just treated, but cured.

Our mission is to deliver breakthrough innovations that extend and improve the lives of people with cancer

We work to prevent cancer where we can and give oncologists more treatment options for their cancer patients that lead to a better quality of life and more time.

Everyone knows someone who has been touched by cancer. When a cancer diagnosis happens, what matters most isn’t what the next scientific breakthrough is – but when it will be available to patients in Switzerland.

Our work in oncology

31

clinical trials involving our cancer medicines in Switzerland (as of 11/2021).

~500

patients currently enrolled in our clinical trials in Switzerland and round about 250 patients are actively on study drug (as of 11/2021).

11

different types of cancer are being studied in our clinical trials Switzerland (as of 11/2021).

Our focus

Our company has a long history of bringing forward innovative medicines. In the field of oncology, we focus on immunotherapy, which aims to activate the body's own immune system to fight the tumor. Our relentless commitment to research and development has enabled us to establish an exceptionally broad research program with more than 1'600 studies. Switzerland is part of this program, currently conducting 31 clinical trials in 11 different tumor types (as of 11/2021). Today, our portfolio includes oncology medicines that treat different cancers and conditions related to cancer treatment.

Access to care

Improving access to cancer care is our strategic priority. We are working with the entire cancer community to help patients gain access to the oncology medicines that they need and to expand the provision of quality cancer care.

The Swiss Oncology team is

  • collaborating with authorities and institutions to ensure access to our medicines
  • working on solutions how to continuously improve the support of healthcare professionals and patients in the treatment of cancer
  • interacting with Oncologists, Scientific leaders and patient organizations to gain insight into market and customer needs.

Progress through partnerships

We work with the entire cancer community - advocacy partners, health care providers, government and industry colleagues - all who share our mission to extend and improve the lives of people with cancer.

Our team has engaged in collaborative efforts to raise the awareness of cancer and improve its prevention, including the creation of regular platforms for stakeholder to advance health policy discussions around cancer care. Furthermore we are a founding member of the multi-stakeholder alliance “All.Can” which aims to exploit efficiency in cancer care.

We participate in several initiatives to support patients with cancer. These include:

  • a website for disease management
  • campaigns to educate the public about early signs and detection
  • a partnership to improve sustainable cancer care all-can.org.

MSD is one of the world 's leading companies in oncology. Visionary research and collaborative action have already led to breakthroughs for the prevention and treatment of certain types of cancer and we're committed to driving further innovation to help change the future of this disease.

Will Wooding

Business Unit Director Oncology · MSD Switzerland

Previous
Next

It takes all of us to beat cancer

As long as doctors are desperate to add years to the lives of their patients, and a world where treatments aren’t accessible to all, we will be here: fighting with all we have to deliver more, sooner.

Clinical studies are the key to gaining new knowledge about the diagnosis and treatment of diseases.

We’re proud to be contributing to this effort in Switzerland.

The ongoing clinical study program in Switzerland includes 31 studies in various cancers (as of 11/2021).

CH-NON-00473, 11/2021